Leading China Hospital Chooses TomoTherapy(R) Technology to Deliver Advanced Cancer Care for Broad Patient Base

MADISON, WI–(Marketwire – June 30, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of highly integrated radiation therapy solutions, announced today that Peking Union Medical College Hospital has selected the TomoTherapy^® treatment system to advance its cancer care capabilities. Located in Beijing, the teaching hospital is one of the most prestigious healthcare facilities in China and a leader in radiation oncology that treats more than 200 patients per day. Peking Union will become the first Ministry of Health system-based general hospital in Beijing to offer TomoTherapy technology.

“After comparing a number of radiation therapy options, we chose a TomoTherapy treatment system in order to provide the most integrated, advanced treatment platform in the world,” said Dr. Fuquan Zhang, chairman of Radiation Oncology at Peking Union Medical College Hospital. “We expect that TomoTherapy will provide advantages compared to traditional delivery methodologies, and that the simple operational platform will help increase throughput for many complex cases, while helping reduce the chance for mistakes. In other words, TomoTherapy is an efficient and advanced system that meets our demanding clinical environment.”

The TomoTherapy treatment system will be used to treat the hospital’s most challenging cases, starting with head, neck and gynecological cancers. The system’s unique helical IMRT capability enables clinicians to deliver highly conformal dose distributions to complex tumors. Additionally, the integrated CT image guidance offered by the TomoTherapy platform allows for precise patient positioning based on internal anatomy at time of treatment. This feature helps increase treatment delivery accuracy and ensure that radiation exposure to surrounding organs and tissue is minimized.

“Peking Union Medical College Hospital has a strong reputation throughout China for its radiation oncology services. With the addition of the TomoTherapy platform, clinicians there can advance their treatment capabilities with IG-IMRT, allowing them to better address more complex cases,” said Paul Baumgart, general manager of TomoTherapy’s Asia-Pacific Operations. “The introduction of TomoTherapy technology at Peking Union will provide a great showcase of the platform’s capabilities for the Chinese market, and is evidence of the growing demand for our solution in Asia.”

The TomoTherapy treatment system was sold to Peking Union Medical College Hospital by the company’s Chinese distributor TomoKnife. The system is expected to be installed later this year.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms “expect,” “expected,” “should” or “will” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TomoMobile, TomoHD, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.